Informasjon

Høyt kolesterol, hyperlipidemi

Vil du vite mer?

Kostråd til pasienter med forhøyet kolesterol
Overvekt og slanking - hvordan lykkes
Kolesterolsenkende legemidler (statiner)
Høyt blodtrykk
Diabetes type 2
Hypotyreose
Høyt alkoholforbruk
Sunt kosthold
Overvekt
Overvekt og fysisk aktivitet - bruk kroppen!
Kolesterolsenkende medisiner
Hjerteinfarkt
Hjerneslag
Dårlig blodsirkulasjon
Røykestopp
Hyperlipidemi - for helsepersonell

Vil du vite mer?

Få tilgang på artikkelen om dette temaet fra Legehandboka.no

Artikkelen inneholder all informasjon norske allmennleger bruker i sitt daglige arbeid.

Jeg har lest og akseptert Brukervilkår ved kjøp av NEL-dokumenter

Dette dokumentet er basert på det profesjonelle dokumentet "Hyperlipidemi". Referanselisten for dette dokumentet vises nedenfor.

Mach F, Baigent C, Catapano A, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal 2020; 41: 111-88. doi:10.1093/eurheartj/ehz455 DOI
Schmidt EB, Hedegaard BS, Retterstøl K. Familial hypercholesterolaemia: history, diagnosis, screening, management and challenges. Heart 2020. pmid:32933999 PubMed
Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 2000; 321: 1497-500. British Medical Journal
Christoffersen M, Frikke-Schmidt R, Schnohr P, et al. Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in generel population. BMJ 2011; 343: d5497. BMJ (DOI)
Durrington P. Dysplipidaemia. Lancet 2003; 362: 717-31. PubMed
Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European . Europena Heart Journal 2016. doi: 10.1093/eurheartj/ehw152 DOI
Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298: 776-85. Journal of the American Medical Association
Norsk kvalitetsforbedring av laboratorieundersøkelser (Noklus). Anbefalte analyser ved ulike kliniske problemstillinger. Lipoproteinforstyrrelser. Siden besøkt 21.09.2020 www.noklus.no
Leren TP, Manshaus TE, Ose L, Berge KE. Lipidprofil hos barn og ungdom med familiær hyperkolesterolemi. Tidsskr Nor Lægeforen 2007; 127: 2363-6. PubMed
Veileder for utredning og behandling av familiær hyperkolesterolemi (FH) i primærhelsetjenesten. UiO 2017. www.nktforfh.no
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018. PMID: 30423393 PubMed
Cooper A, O'Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ 2008; 336: 1246-8. British Medical Journal
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intesnive lowering of LDL cholesterol: a meta-analysis of datat from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81. PubMed
Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol. 2020 Jan;8(1):36-49. PMID: 31862150 PubMed
Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 2020. doi:10.1016/S0140-6736(20)32332-1 DOI
Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. Lancet 2020. doi:10.1016/S0140-6736(20)32233-9 DOI
Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423. BMJ (DOI)
Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 1146-55. PubMed
Sabaté J, Oda K, Ros E. Nut consumption and blood lipid levels. A pooled analysis of 25 intervention trials. Arch Intern Med 2010; 170: 821-7. PubMed
Sabatine MC, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular effects. N Engl J Med 2015. doi:10.1056/NEJMoa1500858 DOI
Hooper L, Summerbell CD, Thompson RL, et al. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev, May 2012. CD002137.pub3. Cochrane (DOI)
Rees K, Dyakova M, Ward K, et al. Dietary advice for reducing cardiovascular risk. Cochrane Database of Systematic Reviews, March 2013. CD002128.pub4. Cochrane (DOI)
Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 1998; 316: 1213-20. British Medical Journal
Nordmann AJ, Nordmann A, Briel M, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166: 285-93. PubMed
Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 2007; 167: 999-1008. PubMed
Kelley GA, Kelley KS, Franklin B. Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. J Cardiopulm Rehabil 2006; 26: 131-9. PubMed
Helsedirektoratet. Nasjonal faglig retningslinje for behandling og rehabilitering ved hjerneslag. Oslo, Helsedirektoratet. Sist oppdatert 21.12.2017 helsedirektoratet.no
Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews 2019, Issue 11. Art. No.: CD006401. DOI: 10.1002/14651858.CD006401.pub5. DOI
Luirink IK, Wiegman A, Kusters M, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med 2019; 381: 1547-56. pmid:31618540 PubMed
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017. pmid:28304224 PubMed
Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis 2018; 277: 483-92. pmid:30270089 PubMed
Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Aug 20;383(8):711-720. PMID: 32813947 PubMed
Græsdal A, Hovland A, Bjørbæk E. Aferesebehandling ved alvorlig hyperkolesterolemi. Tidsskr Nor Lægeforen 2004; 124: 1085-7. PubMed
Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009; 150: 830-9. Annals of Internal Medicine
Bakkebø T. Lipidsenkende midler ved graviditet og amming. Utposten 2014; 3: 46-7 PubMed
Adewale AJ, Flaim D, Lowe RS, et al. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD Study). Am J Cardiol 2010; 106: 1255-63. PubMed
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC exprt consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol 2016; 67: 558-87. doi:10.1016/j.jacc.2015.02.003 DOI
Tsujita K, Sugiyama S, Sumida H, et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention. The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015; 66: 495-507. doi:10.1016/j.jacc.2015.05.065 DOI
Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2014. doi:10.1016/S0140-6736(14)61399-4 DOI
Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. PMID: 25687353 PubMed
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015. doi:10.1056/NEJMoa1501031 DOI
Jones PH, Bays HE, Chaudhari U, et al. Safety of alirocumab (A PCSK9 monoclonal antibody) from 14 randomized trials. Am J Cardiol 2016. pmid:27729106 PubMed
BMJ News. NICE approves new cholesterol lowering drug after NHS strikes deal with manufacturer. BMJ 2021; 374: n2143. www.bmj.com
Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: A systematic review. Am J Med 2009; 122: 962.e1-8.
The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; e-pub.
HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-91. PMID: 23444397 PubMed
Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target. A systematic review. JAMA 2007; 298: 786-98. PubMed
Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014 ;384(9943):618-25. doi: 10.1016/S0140-6736(14)61217-4 DOI
Briel M, Ferreira-Gonzales I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: a systematic review and meta-regression analysis. BMJ 2009; 338: b92. BMJ (DOI)
Hourcade-Potelleret F, Laporte S, Lehnert V, et al. Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis. Heart 2015. doi:10.1136/heartjnl-2014-306691 DOI
Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000; 4: 1-123. PubMed
Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010; 340: c2197. BMJ (DOI)
Park ZH, Juska A, Dyakov D, Patel RV. Statin-associated incident diabetes: a literature review. Consult Pharm. 2014;29(5):317-34. PMID: 24849689 PubMed
Cederberg H, Stančáková A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58(5):1109-17. PMID: 25754552 PubMed
Sattar NA, Ginsberg H, Ray K, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl. 2014;15:1-15. doi: 10.1016/j.atherosclerosissup.2014.04.001.
Ribe AR, Vestergaard CH, Vestergaard M, et al. Statins and risk of intracerebral haemorrhage in a stroke-free population: A Nationwide danish propensity score matched cohort sstudy. EClinicalMedicine 2019; 8: 78-84. doi:10.1016/j.eclinm.2019.02.007 DOI
Mundal LJ, Igland J, Veierød MB, et al. Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia. Heart 2018. pmid:29622598 PubMed

Meld deg på nyhetsbrev

Er du helsepersonell?

Ved å oppgi dette kan du få bedre tilpasset innhold om du har formell helsefaglig kompetanse

Mest lest i dag

Hud

Skabb

Skabb er en hudsykdom som skyldes en skabbmidd som graver ganger i huden og legger egg. Typiske symptomer er plutselig plagsom kløe, som oppleves mest intens om natten.

For helsepersonell

Forårsaker statiner demens?

Det har i en del år vært usikkert om statiner øker risikoen for kognitiv svekkelse og demens. En ny studie har sett på om det er en slik sammenheng.

Livsstil

Symptomer på infeksjon med coronavirus

Symptomene på infeksjon med coronaviruset, COVID-19, er ved sykdommens start nokså like symptomene ved forkjølelse og mild influensa. De mest alvorlige symptomene kommer oftest en stund ut i forløpet av sykdommen.

Høyt kolesterol, hyperlipidemi

Hopp til innhold

Vil du vite mer?

Er du helsepersonell?

Andre leste også dette